An Open-Label Ascending Single-Dose, and Randomized, Double-blind, Placebo-controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CST-2032 in Healthy Volunteers and Subjects With Mild Cognitive Impairment or Parkinson's Disease
Latest Information Update: 03 Apr 2023
At a glance
- Drugs CST-107 (Primary) ; CST-2032 (Primary)
- Indications Mild cognitive impairment; Parkinson's disease
- Focus Adverse reactions
- Sponsors CuraSen Therapeutics
- 30 Mar 2023 According to a CuraSen Therapeutics Media Release, results from this trial will be presented at the International Alzheimer's Disease and Parkinson's Disease (AD/PD'23) conference 2023.
- 30 Mar 2023 Results presented in the CuraSen Therapeutics Media Release.
- 21 Jan 2022 Actual date of last participant enrolled is 24/09/2021 according to Australian New Zealand Clinical Trials Registry record.